The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorAcar, Ramazan
dc.contributor.authorYekedüz, Emre
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorBaytemur, Naziyet Kose
dc.contributor.authorErol, Cihan
dc.contributor.authorCeylan, Furkan Sacit
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2021-06-21T08:46:16Z
dc.date.available2021-06-21T08:46:16Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the start of immunotherapy could lead to decreased OS. Herein, we evaluate the impact of ATB use on OS in RCC patients treated with nivolumab in a multi-center cohort from Turkey. Methods: The data of 93 metastatic RCC patients treated with nivolumab in the second line or later were retrospectively collected from 6 oncology centers. Previous treatments, sites of metastases, International Metastatic RCC Database Consortium risk classification, and ATB use in the three months before (-3) or three months after (+3) the start of immunotherapy were recorded together with survival data. The association of clinical factors with OS and progression-free survival (PFS) was analyzed with univariate and multivariable analyses. Results: The median age was 61 (interquartile range 54-67), and 76.3% of the patients were male. The median OS of the cohort was 23.75 ± 4.41, and the PFS was 8.44 ± 1.61 months. Thirty-one (33.3%) patients used ATBs in the 3 months before (-3) or 3 months after (+3) nivolumab initiation. In the multivariable analyses, ATB exposure (HR: 2.306, 95% confidence interval [CI]: 1.155-4.601, P = 0.018) and the presence of brain metastases at the baseline (HR: 2.608, 95% CI: 1.200-5.666, P = 0.015) had a statistically significant association with OS, while ATB exposure was the only statistically significant parameter associated with PFS (HR: 2.238, 95% CI: 1.284-3.900, P = 0.004). Conclusion: In our study, patients with ATB exposure in the 3 months before or 3 months after the start of immunotherapy had shorter OS. Our findings further support meticulous risk–benefit assessments of prescribing ATBs for patients who are either receiving or are expected to receive immunotherapy.en_US
dc.identifier.citationGuven, D. C., Acar, R., Yekeduz, E., Bilgetekin, I., Baytemur, N. K., Erol, C., ... & Kilickap, S. (2021). The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. Current Problems in Cancer, 100760.en_US
dc.identifier.doi10.1016/j.currproblcancer.2021.100760en_US
dc.identifier.issn0147-0272en_US
dc.identifier.pmid34130864en_US
dc.identifier.scopus2-s2.0-85107853422en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.currproblcancer.2021.100760
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1808
dc.identifier.wosWOS:000723830400020en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherMosby Inc.en_US
dc.relation.ispartofCurrent Problems in Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntibioticen_US
dc.subjectImmune-Checkpoint Inhibitorsen_US
dc.subjectImmunotherapyen_US
dc.subjectMicrobiomeen_US
dc.subjectRenal Cell Carcinomaen_US
dc.titleThe association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
78.pdf
Boyut:
467.4 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu